Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
Authors' conclusion
Over a 24-month period, the addition of ipragliflozin to standard therapy in patients with type 2 diabetes did not change endothelial function assessed by FMD in the brachial artery.
Study context
- Population
- Patients with T2D in the PROTECT study with FMD assessed before and after 24 months of treatment482 in PROTECT
- Participants
- 26 vs 32
- Comparison
- Add-on ipragliflozin vs standard antihyperglycemic treatment
- Ipragliflozinn = 26
- Controln = 32reference
- Primary endpoint
- Endothelial function assessed by flow-mediated vasodilation (FMD)
- Follow-up
- 24 months
Methodological detailssub-analysis, randomized 1:1
- Sub-analysis
- Randomized 1:1
Primary result
As reported in the abstract
FMD, baseline vs 24 months
- Ipragliflozin: FMD baseline vs 24 months 5.2 ± 2.6% vs 5.2 ± 2.6%, no significant difference
- P = 0.98
- Control: FMD baseline vs 24 months 5.4 ± 2.9% vs 5.0 ± 3.2%, no significant difference
- P = 0.34
Further findings
| Outcome | P value |
|---|---|
| HbA1c, baseline vs 24 monthsNo significant difference between changes | P = 0.08 |
HbA1c, baseline vs 24 months
- Ipragliflozin: HbA1c 7.4 ± 0.8% vs 7.0 ± 0.9%, significantly decreased from baseline
- Control: HbA1c 7.4 ± 0.7% vs 7.3 ± 0.7%, not significantly decreased
Original publication
Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study. Cardiovasc Diabetol. Published 20 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →